Acquisition Opportunity BIO-CAT is undergoing an acquisition by Lallemand as of mid-2026, expanding capabilities in enzymes, probiotics, and microbial technologies. This presents a sales window to align on integrated enzyme-microbial solutions, co-marketing opportunities, and continuity for existing BIO-CAT customers during the transition.

US Manufacturing Footprint Post acquisition, there is a strengthened US manufacturing footprint through Lallemand. Target opportunities include scaling production-ready enzyme and microbial formulations, long-term supply agreements, and on-site QA/testing collaborations to support US-based customers seeking reliable supply chain resilience.

Diverse Market Penetration BIO-CAT serves industrial, food, agriculture, and emerging markets with enzyme blends and microbial solutions. Proactively target customers seeking integrated enzyme-microbial offerings, custom formulations, and compliance-driven production (FSSC 22000, GMP) to accelerate adoption.

Quality & Compliance With FSSC 22000 certification for the facility and GMP certification for BIO-CAT Microbials, emphasize premium, safety-focused collaborations. Pursue partnerships with manufacturers and food & nutrition brands prioritizing certified, high-quality ingredients and traceable supply chains.

Active Engagement BIO-CAT has shown momentum through industry events and a multi-channel tech stack (LinkedIn Ads, AWS, CRM/Support tools). Leverage event exposure and digital engagement to nurture leads in Probiota Americas, Sports & Active Nutrition, and Food Ingredients Europe, mapping to potential repeat orders and expanded product lines.